Introduction
The immunopathological characteristics of insulin-dependent diabetes mellitus (IDDM) in the well-defined nonobese diabetic (NOD) mouse model consist of apoptosis as early as 3 weeks of age 1, 1 followed by a progressing insulitis culminating in overt ␤ cell destruction. 2 This sequence of events also appears to occur in humans as well. 3, 4 Although CD4 + and CD8 + T lymphocytes and their production of pro-inflammatory cytokines such as tumor necrosis factor ␣ (TNF␣) and interferon ␥ (IFN␥) play a role in ␤ cell destruction, the trigger for insulitis onset is unknown. 3, 4 Resident macrophages within islets may initiate ␤ cell damage by secreting interleukin-1␤ (IL-1␤) which in turn can lead to the activation of autoreactive lymphocytes in the peripheral lymphoid system upon presentation of ␤ cell-specific antigens. [5] [6] [7] IL-1␤ treatment of murine islets in vitro results in the suppression of ␤ cell function as determined by static glucose-stimulated insulin release assays, associated with IL-1␤-induced activation of both the expression as well as the activity of inducible nitric oxide synthase (iNOS). [5] [6] [7] [8] [9] Inhibition of IL-1␤ binding to the type I IL-1 signaling receptor, using the naturally occurring interleukin-1 receptor antagonist protein (IL-1Ra) was shown to pre-escent protein as controls. Adenoviral gene transfer of human IGF-I prevented IL-1␤-mediated nitric oxide production from human islets in vitro as well as the suppression of ␤ cell function as determined by glucose-stimulated insulin production. Moreover, IGF-I gene transfer prevented IL-1␤-induced, Fas-mediated apoptosis. These results suggest that locally produced IGF-I from cultured islets may be beneficial in maintaining ␤ cell function and promoting islet survival before and following islet transplantation as a potential therapy for type I diabetes. Gene Therapy (2000) 7, 2015-2022.
vent IL-1␤-induced suppression of glucose-stimulated insulin release and nitric oxide (NO) production in vitro in rat and human islets. 6, 7, 10, 11 However, there are conflicting data on the effects of IL-1␤ on human islets. [11] [12] [13] [14] [15] We have demonstrated that islets from recently diagnosed IDDM patients undergo apoptosis in an IL-1␤-dependent manner involving the up-regulation of Fas (CD95) on ␤ cells. 16 Similarly, IL-1␣ can promote the cellsurface localization of Fas in mice. 17 Blockade of nitric oxide (NO) production by chemical inhibition of iNOS prevented Fas up-regulation and Fas-triggered apoptosis in human islets in vitro. 16 The importance of macrophages and macrophage-derived IL-1␤ in IDDM onset derives from several in vivo observations. In the BioBreeding rat, a rat model of IDDM, silica particle depletion of islet macrophages could prevent insulitis onset and IDDM. 18 Furthermore, recombinant IL-1Ra infusion into streptozotocin-treated NOD mice transplanted with syngeneic islets, prevented insulitis of the transplanted islets as well as IDDM. 19 Recent data from our laboratory indicate that high, local production of IL-1Ra from human islets, can suppress IL-1␤-induced, Fas-triggered apoptosis induction in addition to protecting against ␤ cell dysfunction in a NO-dependent manner. 20 Beta cell development and survival is, in part, controlled by the availability of growth factors and, in particular, the insulin-like growth factors (IGFs). [21] [22] [23] [24] The IGFs consist of two potent mitogens, IGF-I and IGF-II. IGF-I expression progressively increases in liver during development ultimately to mediate the growth-promoting effects of growth hormone postnatally. IGF-II plays a prominent role during fetal growth in a wide variety of mammals including humans and is expressed in many tissues postnatally, albeit at lower levels. Although the liver is the major site of IGF-I synthesis, many other tissues are capable of secreting IGF-I in a growth hormone-independent manner. In these tissues, IGF-I acts in a paracrine and/or autocrine fashion and its actions are modulated by six characterized binding proteins. 25 The predominant site of IGF production in rodent and human islets is the ␤ cell, which can also respond to their actions as it possesses the type I IGF signaling receptor. 21, 24 IGFs can act in an autocrine and paracrine manner during islet development as mitogens and they may modulate insulin release postnatally, directly or indirectly through changes in ␤ cell mass or glucose responsiveness. 21, 24 Human fetal pancreas contains IGF-I and appears to secrete IGF-I in a glucose-dependent manner in vitro. 21, 24 In addition to their growth-promoting effects, the IGFs, and IGF-I in particular, display antiapoptotic characteristics, including hematopoietic and myeloid progenitor cells, neurons, cardiomyocytes, and a variety of tumor cell lines. 24, [26] [27] [28] Recently, it was suggested that apoptosis in islets was developmentally regulated and that the peak of apoptosis coincides with low IGF-II and increased iNOS levels. 29 Incubation of islets during the period of peak apoptosis in the presence of IGF-I or IGF-II was able to increase the rate of ␤ cell survival. 29 Although the mechanism of apoptosis was not extensively studied, other data support the involvement of Fas activation. Neonatal rat islets cultured with IL-1␤, TNF␣ and IFN␥, underwent rapid apoptosis when co-incubated with an agonistic anti-Fas antibody. 30 Preincubation with IGF-I, however, prevented IL-1␤-induced, Fas-triggered apoptosis. In a similar study, pretreatment of rat islets with recombinant IGF-I resulted in a decrease of IL-1␤-mediated NO formation by inhibition of iNOS expression and synthesis as well as restoration of glucose-stimulated insulin release. 31 Interestingly, IGF-I treatment of early age NOD mice could decrease the incidence of IDDM as well as the insulitis grade. 32 Administration of recombinant IGF-I to NOD mice was also able to promote the integrity of ␤ cell mass as well as to reduce the incidence of adoptive transfer of IDDM with T cells from diabetic NOD mice. 33, 34 In this article, we have examined the ability of IGF-I gene transfer to islets to confer protection against IL-1␤. We demonstrate that adenoviral gene transfer of the human IGF-I gene into human islets in vitro can prevent IL-1␤-mediated ␤ cell dysfunction, NO production and Fas-triggered apoptosis induction. These results suggest that gene transfer of immunoregulatory cytokines together with growth factors like IGF-I, which promote the integrity and survival of ␤ cells, may be one means of facilitating the survival of islet transplants as a potential therapy for IDDM in humans. 35 
Results
Ad-IGF-I gene transfer to islets results in high IGF-I protein secretion Adenoviral gene transfer to human and murine islets is very efficient [36] [37] [38] with greater than 70% of islet cells being transduced. 20 We have demonstrated that infection of human islets with recombinant, replication-defective adenoviruses deleted for E1 and E3 results in very high levels of transgene expression without affecting the ability of the ␤ cells to respond normally to a glucose challenge. 20 We routinely infected groups of 200-300 islets within 48-72 h following islet isolation from cadaveric donor pancreas. To examine the effects of IGF-I on islets following gene transfer, islets were infected with Ad-IGF-I as well as Ad-eGFP and Ad-LacZ at identical p.f.u. (1 × 10 6 ) in a minimal volume of serum-free medium. IGF-I protein was detected in the culture supernatant using a commercially available ELISA kit in which IGF-I was measured following acid-ethanol extraction to remove IGF binding proteins. IGF-I in the media of uninfected islets was detectable (28.4 ± 2.6 ng/ml), however, in Ad-IGF-I-infected islets, a significantly higher level of IGF-I (102.8 ± 34.2 ng/ml; Table 1 ) was detected.
Prevention of IL-1␤-induced suppression of glucosestimulated insulin release as well as nitric oxide production with adenoviral gene transfer of IGF-I to human islets in vitro To determine if IGF-I is able to block the effects of IL-1␤ on islet ␤ cell function, intact infected islets were treated with 50 units of recombinant IL-1␤ . This amount of IL-1␤ is sufficient to impair the ability of islets to respond to a high glucose concentration (18 mm), both in uninfected islets as well as in those infected with the Ad-LacZ control virus ( Figure 1 ). Islets infected with Ad-IGF-I secreted higher insulin relative to uninfected and AdLacZ-infected islets when exposed to glucose at 5 mm final concentration. The difference was statistically significant (430 ± 18.4% from Ad-IGF-I-infected islets versus 113 ± 80% in Ad-LacZ-infected islets where uninfected islets exposed to 5 mm glucose are taken to represent 100% as control, P Ͻ 0.05). As shown in Table 2a ,1 Ad-IGF-I-infected islets were refractory to the effects of IL-1␤ in the presence of high glucose and secreted significantly more insulin at 18 mm glucose than islets exposed to 5 mm. The difference was statistically significant (P Ͻ 0.05). In Figure 1b and Table 2B , we show that the same protective effect can be achieved with lower titers of Ad-IGF-I, however, there is a lower limit at which no protection is conferred (1 × 10 4 p.f.u. and less). As NO has been shown to be an important determinant of the suppression of IL-1␤-induced impairment of glucose-stimulated insulin secretion, we evaluated the level of nitrite in the culture supernatant of mock-infected, AdLacZ-and Ad-IGF-I-infected islets in the presence or absence of 50 units of IL-1␤ using the Griess reagent. Mock-infected islets as well as those infected with AdLacZ produced a basal amount of NO in the absence of any IL-1␤ ( Figure 2 ). There was a significant increase of NO production when islets were exposed to 50 units of IL-1␤ (213 ± 15.3% relative to control, P Ͻ 0.05). Ad-IGF-I-infected islets did not produce NO at significantly higher levels than mock-infected or Ad-LacZ-infected islets which were not exposed to IL-1␤ (Ad-IGF-I: 100 ± 5%, Ad-LacZ: 116 ± 10% relative to uninfected control islets). In the presence of IL-1␤, however, Ad-LacZinfected islets displayed a significant increase in NO production relative to uninfected islets exposed to IL-1␤ (375 ± 40% versus 213 ± 15.3% IL-1␤-treated uninfected islets, P Ͻ 0.05). Finally, Ad-IGF-I-infected islets exposed to IL- Detection of human IGF-I by ELISA in the conditioned media of human islets. Groups of 200 islets were infected with 1 × 10 6 p.f.u. of Ad-IGF-I or mock-infected as described in Materials and methods. The media were collected 48 h following infection and IGF-I was measured.
Figure 1 (a) Adenoviral gene transfer of IGF-I to human islets prevents the IL-1␤-induced impairment of glucose
1␤ produced NO at levels no higher than mock-infected islets unexposed to IL-1␤ (Ad-IGF-I: 100 ± 5.8% versus control; IL-1␤-treated islets: 213% ± 15.3% versus control, P Ͻ 0.05 Ad-IGF-I versus uninfected islets in the presence of IL-1␤). These results demonstrate that IGF-I is able to block completely the production of NO in response to IL-1␤. Human islets infected with Ad-IGF-I are protected from IL-1␤-stimulated, Fas-triggered apoptosis activation in vitro To examine the effect of IGF-I on Fas-mediated apoptosis, an agonistic Fas antibody was used to induce apoptosis in untreated mock-infected and infected islets in the absence or presence of IL-1␤. We assessed caspase-3 activity as a marker of apoptosis induction since recent reports demonstrate that it is specifically activated in response to the same Fas antibody. [39] [40] [41] [42] Ad-eGFP was used as a control virus that we have shown does not affect function or apoptosis of human islets in vitro, similar to Ad-LacZ. 20, 43 IL-1␤ was added to mock-infected, Ad-eGFP and Ad-IGF-I-infected islets and the agonistic antibody was then added for 1 h. Caspase-3 activity was normalised to the number of cells in the lysate by an indirect quantitative method whereby the amount of DNA is evaluated using a fluorescent intercalating agent.
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As shown in Figure 3a , caspase-3 activity was significantly suppressed in islets infected with Ad-IGF-I compared with uninfected islets (23 ± 5% relative to control, where 100% represents the caspase-3 activity in mockinfected, untreated islets, P Ͻ 0.05). There were no significant differences in caspase-3 activity among untreated, uninfected islets and those exposed to IL-1␤ or the agonistic antibody CH-11. Pretreatment of uninfected islets with IL-1␤ followed by exposure to CH-11 resulted in a significant increase in caspase-3 activity (307 ± 10.7% in IL-1␤ + CH-11-treated islets versus 137 ± 1.3% in IL-1␤-treated islets alone and 101 ± 3.7% in islets treated only with CH-11, P Ͻ 0.05 for IL-1␤ + CH-11 versus control). The reduction in caspase-3 activity in Ad-IGF-Iinfected islets compared with control, was abolished in Ad-IGF-I-infected islets exposed to IL-1␤, however, the level was almost identical to that in control islets. The most striking observation was the suppression of IL-1␤-stimulated, Fas-triggered caspase-3 activation in islets infected with Ad-IGF-I (Figure 3a) . Compared with uninfected islets and those infected with Ad-eGFP that were exposed to IL-1␤ and the agonistic CH-11 antibody, IGF-I-expressing islets exhibited statistically significant lower levels of caspase-3 (40 ± 20% compared with 307 ± 10.7% in control islets or 313 ± 14% in Ad-eGFP-infected islets; P Ͻ 0.05 in both cases). We also examined the insulin secretion of Ad-IGF-I-infected islets in response to glucose following the sequential addition of IL-1␤ and CH-11 to the cultures. In Figure 3b we show that there was no significant effect on insulin response following the combined cytokine/antibody treatment.
Discussion
In this article, we demonstrate that adenoviral gene transfer of the human IGF-I gene to human islets in vitro can suppress the IL-1␤-induced impairment of glucosestimulated insulin secretion. It is important to note that adenoviral infection of intact human islets in culture does not change their viability or functional characteristics at multiplicities of infection we and others have used 20, 37, 38, 43, 44 and in vivo, murine islets infected with adenoviral vectors have survived for up to 20 weeks without any evidence of impairment. 45 At low glucose concentration (5 mm), islets infected with Ad-IGF-I produce significantly more insulin than uninfected islets or those infected with Ad-LacZ. Ad-IGF-I infection was able
Figure 3 (a) Infection of human islets in culture with an adenoviral vector expressing human IGF-I can suppress IL-1␤-stimulated, Fas-triggered activation of apoptosis. Two hundred to 300 islets were infected with 1 × 10 6 p.f.u. Ad-eGFP, Ad-IGF-I or mock-infected and then treated with 50 units of IL-1␤ for a period between 18 and 24 h. Immediately thereafter, 250 ng of an agonistic anti-Fas antibody were added to each group and the islets were lysed 1 h later. Caspase-3 activity was detected as described in Materials and methods and the value was corrected for cell number indirectly, by assessing the amount of DNA present in the lysate. The bars indicate the means of three independent experiments performed in triplicate and the error bars denote the s.e.m. We show the means as percent of control where the ratio of caspase-3 activity to DNA content in uninfected, untreated islets represents 100%. (b) Glucose-stimulated insulin secretion of islets following sequential exposure to 50 units IL-1␤ and CH-11 antibody. Two hundred to 300 islets were treated identically as indicated above and then assayed for insulin release by ELISA following glucose addition. The results are derived from triplicate determinations and are presented as actual IU/ml of insulin secreted into the culture supernatant. Bars indicate the means and error bars the s.e.m.
to block the inhibitory effects of IL-1␤ on glucosestimulated insulin secretion, NO production and Fasdependent apoptosis activation.
Although several reports suggest that IGF-I inhibits insulin secretion in vivo and in certain instances in vitro, [46] [47] [48] [49] one study suggests that IGF-I actually potentiates glucose-stimulated insulin release from cultured human islets. 50 Another study suggests that IGF-I has a dual effect on glucose-stimulated insulin release from isolated islets in culture that is IGF-I-and glucose concentration-dependent. 51 Based on those observations, we calculate that the IGF-I output between the time of Ad-IGF-I infection and static glucose-stimulated insulin release assay was well below the concentration able to inhibit insulin release significantly. In fact, the in vivo suppression of insulin secretion by IGF-I administration may be secondary to IGF-I effects at the peripheral level on liver and adipose tissue. 50 We observed no increase in NO production in Ad-IGF-I-infected islets exposed to IL-1␤ compared with the increase seen in the mock-infected islet cultures treated with IL-1␤. Ad-IGF-I infection alone did not change the NO levels compared with uninfected, untreated islets. In contrast, Ad-LacZ infection followed by IL-1␤ treatment, resulted in a dramatic increase in NO production that was paralleled by an increase in IL-1␤-induced, Fas-triggered apoptosis activation in Ad-eGFP-infected islets, as measured by caspase-3 levels (see Figure 3a) . The increased nitrite accumulation by Ad-LacZ-infected islets in the presence of IL-1␤ suggests that the adenoviral infection triggers intrinsic islet antiviral defense mechanisms that are perhaps mediated by resident macrophages and potentiated by exogenously added IL-1␤. More importantly, adenoviral infection has been shown to stimulate NO production. 52, 53 It is possible that the nitrite detected in the Ad-LacZ-infected islets derived from islet-resident antigen presenting cells that were activated in response to the viral proteins. Antigen presenting cells respond to viral infection by producing NO, [54] [55] [56] [57] however, their low numbers (less than 15 macrophages and dendritic cells per islet) could explain the small increase we observed compared with control.
The basal NO production by uninfected, untreated islets as well as the detectable caspase-3 activity in parallel, may reflect a natural response to trauma that the islets were subjected to at the time of pancreas procurement and/or during the islet isolation procedure. Furthermore, the removal of islets from the pancreas may deprive them of trophic factors which naturally suppress proapoptotic events, including nitric oxide formation. Ad-IGF-I infection, however, was able to prevent the IL-1␤-induced, Fas-triggered activation of caspase-3 activity. Basal caspase-3 activity in islets was also significantly reduced following Ad-IGF-I infection, demonstrating the anti-apoptotic property of IGF-I. Finally, Ad-IGF-I-infected islets appear to be sensitive to IL-1␤-stimulated, but not to Fastriggered caspase-3 activation, although the enzyme activities in both groups are lower than those observed in untreated, uninfected islets. Why the level of caspase-3 is higher in Ad-IGF-I-infected islets exposed to IL-1␤ than that in infected islets treated only with the agonistic CH-11 antibody is not known at present. Clearly, however, there are differences in the signal transduction pathways between the IL-1 and the Fas pathways. IGF-I might act on either of the two pathways (IL-1 or Fas) more effectively than the other.
Although there is strong support for IL-1␤ alone inducing NO production and ␤ cell dysfunction in rat islets, this does not always appear to be the case for human beta cells. 5, [12] [13] [14] 58, 59 There are instances, however, where in human islets, IL-1␤ alone promotes significant NO production and ␤ cell impairment in agreement with our findings. [12] [13] [14] 16, 20, 60 While it is not readily apparent why there is such variability between the data between different investigators and experiments, factors that could have influenced our findings that we can rule out include: (1) the degree of islet contamination by nonendocrine, exocrine or other pancreatic cells is minimal; (2) variability of islet viability and function; and (3) isolation-associated cell damage. One important difference between our procedures and those in some other studies where IL-1␤ alone could not promote NO production or ␤ cell impairment involves the culture conGene Therapy ditions of the islets following isolation. It is possible that different culture conditions may promote ␤ cell resistance to the effects of IL-1␤ by inducing the down-regulation (internalization) of the type I IL-1 receptor. This would have the effect of suppressing basal NO production and increasing the threshold for IL-1␤ sensitivity. Consequently, the relocation of the type I IL-1 receptor to the cell surface would require stimulation by cytokines like TNF␣ or IFN␥. Both human and rodent islets have been well-characterized in their ability to produce IGFs and their binding proteins. 21, 22, 24, 61 In particular, IGF-I acts as a paracrine and autocrine factor to stimulate DNA synthesis and may act as a survival factor, in addition to IGF-II, which has been suggested to prevent apoptosis during islet maturation, at least in rats. 29 The anti-apoptotic effects of IGF-I have been documented in transformed cell lines, neurons, and hematopoietic progenitor cells. [62] [63] [64] [65] [66] [67] [68] Furthermore, recent evidence suggests that IGF-I pretreatment of islets in culture can prevent ␤ cell impairment as well as Fas-triggered cell death induced by a combination of IL-1␤, TNF␣ and IFN␥. 30 Although Ad-IGF-I gene transfer to islets can protect them from the effects of IL-1␤, we have shown that it is unable to provide protection from Fas-induced apoptosis activation mediated by a cytokine cocktail consisting of TNF␣, IL-1␤ and IFN␥ (data not shown). However, given that there is evidence demonstrating a central role of IL-1␤ and only potentiating roles of TNF␣ and IFN␥ on mediating islet dysfunction in vitro, it is likely that IGF-1 expression will be beneficial in vitro and in vivo. 6, 7 Apoptosis is a process involving the activity of caspases. To date, caspase-3 activation commits all cells examined, including ␤ cells to apoptosis and is an early step in mediating Fas signalling. 17, [69] [70] [71] [72] In response to Fas ligation by the CH-11 monoclonal antibody, caspase-3 activation is seen as early as 5 min in a fibrosarcoma cell line. 39 While we have not formally ruled out the possibility that caspase-3 activity in our cultures partly derives from non-␤ cells, that caspase-3 activity is at control levels in islets expressing IGF-I demonstrates the utility of IGF-I to protect all islet cells from the apoptotic Fas trigger.
Although it is unclear exactly how IGF-1 expression in islets regulates apoptosis, IGF-1 has been implicated in blocking apoptosis through several different pathways. In particular, IGF-I binding to the type I IGF receptor activates phosphatidylinositol-3 kinase (PI3K) which has been shown to be involved in the suppression of apoptosis. 73 IGF-I signaling through PI3K apparently can prevent the processing of ICE/LAP3 protease as well as that of procaspase-3. 74 Furthermore, IGF-I can attenuate Bax induction as well as caspase-3 activation in cardiomyocytes, thereby preventing apoptosis. 75 IGF-I could also prevent apoptosis in PC12 pheochromocytoma cells as well as interleukin-3-deprived BaF3 cells by up-regulating bcl-x L production. 76, 77 Caspase-3 activation was also inhibited in IL-3-deprived, IGF-I-treated BaF3 cells. 78 IGF-I is able to suppress c-myc-sensitized, Fas-activated apoptosis downstream of the Fas antigen, perhaps at the level of bcl-2 79 and rat fibroblasts can be protected from apoptosis with IGF-I through the Akt kinase (protein kinase B)/PI3K pathway. 80 Akt kinase is expressed in rat pancreatic islets as well as in a variety of rat ␤ cell lines and more importantly, IGF-I leads to a phosphorylation and activation of Akt kinase in these cells. 81 In this article, we have demonstrated the feasibility of using an adenoviral vector encoding IGF-I to infect human islets as a means of preventing IL-1␤-induced impairment of ␤ cell function. Moreover, we have demonstrated that IGF-I production from the genetically modified islets can suppress NO production in the presence of IL-1␤ as well as Fas-triggered caspase-3 activation, an early marker of apoptosis induction. Based on these results, we suggest that IGF-I gene transfer to islets may be a means of preserving their integrity and promoting their survival and function before and following transplantation into diabetic hosts as a potential therapy for type I diabetes.
Materials and methods
Generation of recombinant adenoviruses E1-deleted adenoviruses containing cassettes encoding the reporter genes ␤ galactosidase (Ad-LacZ) and enhanced green fluorescent protein (Ad-eGFP), and the cDNA of IGF-I (Ad-IGF-I), were generated as described 82, 83 by Cre-lox recombination in CRE8 cells. The LacZ transgene encodes ␤ galactosidase. Briefly, the transgene cDNAs (␤ galactosidase, eGFP or IGF-I) were inserted into the pAdlox shuttle plasmid containing the CMV promoter. E1-substituted recombinant adenovirus was generated by cotransfection of SfiI-digested pAdloxtransgene and 5 helper virus DNA into the adenoviral packaging cell line CRE8, propagated and purified as described. 82, 83 Isolation and culture of human islets Human islets were obtained from the Diabetes Research Institute of the University of Miami (Dr Camillo Ricordi) as well as from the University of Minnesota (Dr Bernhard Hering) which are part of the Juvenile Diabetes Foundation International Islet Distribution Program. Pancreata were obtained from at least 20 cadaveric donors of different ages and sex and subjected to digestion, isolation and purification as described. 84 For each experiment, islets from at least five donors were used. The purity of islets was usually greater than 80% (mantled islets). Viability of the cultured islets as assessed by vital dye exclusion, insulin staining and morphology was routinely greater than 85%.
Gene transfer of ␤-galactosidase, eGFP and human IGF-I to islets in culture using E1-E3-deleted adenoviral vectors Islets were washed twice in serum-free RPMI 1640 (Gibco-BRL, Rockville, MD, USA) supplemented with a 1% penicillin/ streptomycin solution (Gibco-BRL) before infection. Two hundred to 300 islets were infected with Ad-LacZ, Ad-eGFP or Ad-IGF-I at a p.f.u. (plaque forming units) of 1 × 10 6 in a minimal volume of serum-free RPMI 1640 for 2-4 h at 37°C. To assess the effect of viral titer on protective effects, we also infected islets with 1 × 10 3 -1 × 10 6 p.f.u./200 islets. Following the infection, the islets were washed twice in serum-free medium and then once with medium containing 10% heat-inactivated fetal calf serum (Gibco-BRL). Islets were then incubated at 37°C in medium with serum for 2 days after which all the assays were carried out. All the functional assays described below were performed in triplicate on at least three different occasions unless otherwise indicated.
Detection of secreted transgene products and evaluation of ␤ cell function following IL-1␤ treatment Secreted IGF-I protein was detected in the culture supernatants 2 days following infection using commercially available ELISA kits (IDL Laboratories, San Leandro, CA, USA). This also coincided with the day of IL-1␤ treatment in the designated cultures. To assess the effects of IL-1␤ on ␤-cell function of genetically modified and unmodified islets, we used glucose-stimulated insulin secretion as a functional assay. Islets were first treated with 50 U of recombinant human IL-1␤ (Sigma, St Louis, MO, USA) for a period between 18 and 24 h immediately following a pre-incubation in fresh media between 16 and 24 h. The IL-1␤-containing medium was removed and the islets were washed twice with Krebs-Ringer-Hepes buffer (KRH buffer; 25 m, Hepes pH 7.4, 115 mm NaCl, 24 mm NaHCO 3 , 5 mm KCl, 2.5 mm CaCl 2 , 1 mm MgCl 2 ). Incubation was carried out at 37°C in KRH buffer for 30 min followed by an additional incubation for 30 min in the presence of 5 and 18 mm glucose (final concentration). The buffer was subsequently removed and its insulin content was determined by a commercially available ELISA kit (Dako Chemicals, Carpinteria, CA, USA) which specifically recognizes processed human insulin.
In order to evaluate NO production, the islet culture supernatants were collected between 18 and 24 h following the addition of IL-1␤ and an aliquot was subjected to the Griess reaction.
Assessment of apoptosis activation in vitro
Uninfected islets, as well as those infected with Ad-LacZ or Ad-IGF-I were treated with 50 units IL-␤ for 24 h as described above. Furthermore, a subset of islets (pretreated or not with IL-1␤) were challenged with the agonistic human Fas antibody (clone CH-11; Upstate Biotechnology) for 1 h at 37°C. At the end of the incubation, islets were lysed and processed for the detection of caspase-3 (CPP32) activity using a commercially available kit (ApoAlert; Clontech, Palo Alto, CA, USA). As an indirect means of correcting for cell number, the CPP32 activity was corrected by the number of nanograms of DNA in the lysate assayed, using the PicoGreen reagent, an intercalating DNA fluorogenic compound (Molecular Probes, Eugene, OR, USA).
Statistics
Statistics were performed using the SPSS for Windows v. 8.0 package and a P value less than 0.05 by ANOVA was taken to indicate statistically significant differences.
